+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alpha Thalassemia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 120 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5707262
Description Jump to:

Industry Outlook

Alpha thalassemia treatment market accounted for a market value of US$ 643.4 Mn in 2021 and projected to grow at a CAGR of 7.1% during the forecast period from 2022 to 2030. Alpha thalassemia is a congenital autosomal recessive disorder caused due to absence or reduction in alpha globin peptides due to a deletion or mutation of the alpha globin genes. Alpha thalassemia usually found in Africa, the Middle East, India, Southeast Asia, southern China, and the Mediterranean region. The key factors responsible for growth of alpha thalassemia treatment market are the rising awareness associated with thalassemia in medical practitioners & public, and support provided by government & non-government organizations to manage and treat thalassemia.

Deferasirox being the only approved drug for alpha thalassemia treatment will dominate the market throughout the forecast period

In 2021, deferasirox will dominate the market throughout the forecast period as it is the only approved drug therapy by USFDA for alpha thalassemia. According to market experts, deferasirox possess efficient oral bioavailability and a long half-life appropriate for once-daily dosing. Overall, deferasirox is similar to deferoxamine in reducing liver iron and serum ferritin levels in a dose-dependent style. It is use widely across the world for alpha thalassemia treatment because its once-per-day oral dosage. However, Darbepoetin Alfa is present in phase III of clinical trials and expected to get approval very soon but there are a few drawbacks observed in the Phase IIa that might have some effect on its approval. If it gets approved it will be observed as the fastest growing drug in this market.

Increasing awareness related to the treatment & management of alpha thalassemia in Asia Pacific makes it the fastest growing region throughout the forecast period

The Asia Pacific will grow gradually throughout the forecast period from 2020 to 2030, the key factors responsible for growth of alpha thalassemia treatment market in this region are rising awareness related to alpha thalassemia treatment & management and increasing support provided by governmental & non-governmental organizations to develop awareness in public. According to market experts, alpha-thalassemia is specifically common among Southeast Asian population descent 1-30% of the population has a thalassemia trait; up to 40% may be a genetic carrier.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Alpha Thalassemia Treatment market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Alpha Thalassemia Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Type

  • Folic Acid
  • Deferasirox
  • Deferiprone
  • Hydroxyurea

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Alpha Thalassemia Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Alpha Thalassemia Treatment market?
  • Which is the largest regional market for Alpha Thalassemia Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Alpha Thalassemia Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Alpha Thalassemia Treatment market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Alpha Thalassemia Treatment Market
2.2. Global Alpha Thalassemia Treatment Market, By , 2021 (US$ Million)
2.3. Global Alpha Thalassemia Treatment Market, By Drug Type, 2021 (US$ Million)
2.4. Global Alpha Thalassemia Treatment Market, By Geography, 2021 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2021
3. Alpha Thalassemia Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Alpha Thalassemia Treatment Market Vendors
3.2. Strategies Adopted by Alpha Thalassemia Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Alpha Thalassemia Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Alpha Thalassemia Treatment Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
6. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Folic Acid
6.3.2. Deferasirox
6.3.3. Deferiprone
6.3.4. Hydroxyurea
7. North America Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
7.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
7.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
7.4.1.1.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
7.4.1.2.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
7.4.1.3.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
8. UK and European Union Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
8.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
8.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
8.4.1.1.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
8.4.1.2.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
8.4.1.3.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
8.4.1.4.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.5. France
8.4.1.5.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
8.4.1.5.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
8.4.1.6.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
9. Asia Pacific Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
9.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
9.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
9.4.1.1.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
9.4.1.2.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.3. India
9.4.1.3.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
9.4.1.3.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
9.4.1.4.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
9.4.1.5.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
9.4.1.6.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
10. Latin America Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
10.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
10.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
10.4.1.1.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
10.4.1.2.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
10.4.1.3.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
11. Middle East and Africa Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
11.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
11.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
11.4.1.1.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
11.4.1.2.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
11.4.1.3.1. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
12. Company Profile
12.1. GlaxoSmithKline Plc
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Bellicum Pharmaceuticals
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Acceleron Pharma
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Johnson & Johnson
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Merck & Co Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Alnylam Pharmaceuticals Inc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Calimmune Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Editas Medicine Inc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Gilead Sciences Inc.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
List of Figures
Figure 1 Global Alpha Thalassemia Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Alpha Thalassemia Treatment Market: Quality Assurance
Figure 5 Global Alpha Thalassemia Treatment Market, By , 2021
Figure 6 Global Alpha Thalassemia Treatment Market, By Drug Type, 2021
Figure 7 Global Alpha Thalassemia Treatment Market, By Geography, 2021
Figure 8 Market Geographical Opportunity Matrix - Global Alpha Thalassemia Treatment Market, 2021
Figure 9 Market Positioning of Key Alpha Thalassemia Treatment Market Players, 2021
Figure 10 Global Alpha Thalassemia Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 11 Global Alpha Thalassemia Treatment Market, By , 2021 Vs 2030, %
Figure 12 Global Alpha Thalassemia Treatment Market, By Drug Type, 2021 Vs 2030, %
Figure 13 U.S. Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 14 Canada Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 15 Rest of North America Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 16 UK Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 17 Germany Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 18 Spain Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 19 Italy Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 20 France Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 21 Rest of Europe Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 22 China Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 23 Japan Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 24 India Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 25 Australia Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 26 South Korea Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 27 Rest of Asia Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 28 Brazil Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 29 Mexico Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 30 Rest of Latin America Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 31 GCC Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 32 Africa Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
Figure 33 Rest of Middle East and Africa Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 2 Global Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 3 North America Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 4 North America Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 5 U.S. Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 6 U.S. Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 7 Canada Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 8 Canada Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 9 Rest of North America Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 10 Rest of North America Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 11 UK and European Union Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 12 UK and European Union Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 13 UK Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 14 UK Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 15 Germany Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 16 Germany Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 17 Spain Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 18 Spain Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 19 Italy Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 20 Italy Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 21 France Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 22 France Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 23 Rest of Europe Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 24 Rest of Europe Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 25 Asia Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 26 Asia Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 27 China Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 28 China Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 29 Japan Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 30 Japan Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 31 India Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 32 India Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 33 Australia Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 34 Australia Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 35 South Korea Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 36 South Korea Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 37 Latin America Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 38 Latin America Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 39 Brazil Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 40 Brazil Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 41 Mexico Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 42 Mexico Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 43 Rest of Latin America Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 44 Rest of Latin America Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 45 Middle East and Africa Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 46 Middle East and Africa Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 47 GCC Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 48 GCC Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 49 Africa Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 50 Africa Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
Table 51 Rest of Middle East and Africa Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
Table 52 Rest of Middle East and Africa Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)

Companies Mentioned

  • GlaxoSmithKline Plc
  • Bellicum Pharmaceuticals
  • Novartis AG
  • Acceleron Pharma
  • Johnson & Johnson
  • Merck & Co Inc.
  • Alnylam Pharmaceuticals Inc.
  • Calimmune Inc.
  • Editas Medicine Inc.
  • Gilead Sciences Inc.

Related Topics

Related Reports

Thalassemia Treatment Market by Type, Indication Type, End-Users - Global Forecast 2025-2030 - Product Image

Thalassemia Treatment Market by Type, Indication Type, End-Users - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Thalassemia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Thalassemia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Hemoglobinopathies Market by Indication, Treatment, Diagnosis, End-User - Global Forecast 2025-2030 - Product Image

Hemoglobinopathies Market by Indication, Treatment, Diagnosis, End-User - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Thalassemia Treatment - Global Strategic Business Report - Product Image

Thalassemia Treatment - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Thalassemia Market Size, Share and Trends Analysis Report by Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy), Type (Alpha Thalassemia, Beta Thalassemia), and Region 2024-2030 - Product Image

Thalassemia Market Size, Share and Trends Analysis Report by Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy), Type (Alpha Thalassemia, Beta Thalassemia), and Region 2024-2030

  • Report
  • 80 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.